Oak vs He & She MD
Oak's recorded checkout did not match its advertised $119, $167 and $190 entry figures. He & She MD's $99 is a monthly equivalent on an upfront annual payment.
Disclosure: GLP Loss is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. How we make money.
Oak
Partner
$250/mo
The checkout charges $250 a month for compounded semaglutide and $300 for tirzepatide, not the lower figures the marketing pages advertise. That same checkout states the charge rises at each dose step, so the flat-price claim does not survive its own FAQ.
- No subscription and no automatic renewal charge, stated at checkout
- The dispensing pharmacy is named
- A real state list is published rather than a claim of nationwide coverage
- Compounded and branded priced side by side at checkout
- The flat-dose claim is contradicted by the checkout's own dose-step disclosure
- Each dose step is stated to add roughly $50 to $75
- Three entry figures across three pages, none of them matching the checkout
- $250 sits above the middle of this market before any escalation
Pick it for: Keeping your exposure to one fill while you titrate
Not for: Anyone choosing Oak for a price that holds as the dose climbs.
He & She MD
Editorial
$99/mo
Every headline is an annual prepay: $99 a month for injectable semaglutide means $1,188 charged today, and $159 for tirzepatide means $1,908. The oral runs $199 for six months and renews above that.
- Every annual total is published in dollars
- $1,188 divides to an exact $99 month
- The oral renewal rate is disclosed
- Fifty states
- The $99 rate requires $1,188 at enrollment
- Tirzepatide asks $1,908 before the first dose
- The oral renews 20% above its opening rate
- Oral and injectable sit on different terms
Pick it for: Buyers who will not be shopping again this year
Not for: Anyone who needs to pay month by month.
Our verdict
The Oak checkout recorded in our review listed different prices from the three marketing pages. That mismatch is a reason to obtain the final quote, not proof that every buyer receives the same charge. He & She MD's $99 represents a twelfth of an annual payment due before the first shipment, rather than a one-month purchase. Oak's three-month prescription is also billed upfront. Compare the amount due now, the supply it covers and the renewal terms; an advertised monthly equivalent does not by itself establish any of those.
What actually separates them
Oak and He & She MD differ on published price, names its pharmacy and where you can use it. The table summarizes those terms; confirm any details it does not cover with the provider.
Oak’s comparison figure is $151 higher than He & She MD’s — a 153% difference between the listed rates. These figures do not establish equivalent prescribed doses, supply or care. Confirm the selected product, full payment obligation and next charge.
At unchanged rates, a twelve-month illustration is about $1,188 at He & She MD against $3,000 at Oak — a difference of $1,812. This is not a quote for a year of care: actual charges depend on prescribed supply, purchase terms and renewals.
| Oak | He & She MD | |
|---|---|---|
| Published price | $250/mo | $99/mo |
| Names its pharmacy | Yes | No |
| Where you can use it | US except WV and MS | 50 states |
Before you choose either
Whether these two publish a milligram dose is not settled in our records for both of them, so treat the two prices as not yet comparable and ask each what dose the monthly figure buys. Set the answers against every published price we hold — a lower monthly price at a smaller dose is not the cheaper option.
Our take is computed from a published rubric that does not read commercial status, and what is known about safety applies to both of them equally.